Clinical Trial Detail

NCT ID NCT02279394
Title Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

smoldering myeloma

Therapies

Dexamethasone

Elotuzumab + Lenalidomide

Age Groups: adult

No variant requirements are available.